Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial

Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial

Abstract Objectives The hypothesis of the study is that treatment with hydroxychloroquine sulphate in hospitalised patients with coronavirus disease 2019 (Covid-19) is safe and will accelerate the virological clearance rate for patients with moderately severe acute respiratory syndrome coronavirus 2...

Full description

Bibliographic Details
Main Authors: Magnus Nakrem Lyngbakken, Jan-Erik Berdal, Arne Eskesen, Dag Kvale, Inge Christoffer Olsen, Anbjørg Rangberg, Christine Monceyron Jonassen, Torbjørn Omland, Helge Røsjø, Olav Dalgard
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Trials
Subjects:
COVID-19
Randomized controlled trial
Protocol
Chloroquine
Pragmatic trial
Polymerase chain reaction
Online Access:http://link.springer.com/article/10.1186/s13063-020-04420-0

Internet

http://link.springer.com/article/10.1186/s13063-020-04420-0

Similar Items